As the highly transmissible COVID-19 omicron subvariant BA.5 now accounts for 53.6 percent of cases in the U.S., concerns are rising over the potential for a new surge. However, experts predict it will not be as devastating as past surges.
Public Health
Officials in President Joe Biden's administration are considering plans to make second COVID-19 boosters available to all adults as part of the White House's larger strategy to combat a rise in cases and hospitalizations driven by the BA.5 omicron subvariant.
A total of 866 monkeypox cases have been confirmed across 40 states and Washington, D.C., as of July 11, CDC data shows. Globally, cases have surpassed 9,000, with some health experts urging the outbreak to be recognized as an emergency.
Some experts are questioning why the federal government is not taking a stronger stance on masking amid rising transmission and hospitalization rates driven by the highly transmissible BA.5 omicron subvariant.
COVID-19 hospitalizations and deaths will remain stable through late July, while cases will continue to rise as the highly transmissible omicron subvariant BA.5 spreads nationwide, according to the CDC's latest disease forecasting models.
BA.2.75 is the latest omicron relative catching experts' attention, with three cases recently identified on the West Coast, Time reported July 11.
President Joe Biden said he is weighing whether to consider declaring abortion access a public health emergency, The Washington Post reported July 10.
COVID-19 cases dipped nationwide in the past week, though the number of areas with high levels of community spread is rising as the highly transmissible omicron subvariant BA.5 remains dominant in the U.S., according to the CDC's COVID-19 data tracker…
Of the 19.5 million children younger than 5 in the U.S., more than 267,000 have received their first COVID-19 shot, ABC News reported July 7.
The highly transmissible omicron subvariant BA.5 will likely spur another wave of COVID-19 infections in the U.S., Eric Topol, MD, founder and director of the Scripps Research Translational Institute in San Diego, told The New York Times.